Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
137 hedge funds and large institutions have $522M invested in Aerie Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 22 closing their positions.
208% more call options, than puts
Call options by funds: $3.27M | Put options by funds: $1.06M
37% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 38
4% less funds holding
Funds holding: 142 → 137 (-5)
18% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 22
28% less capital invested
Capital invested by funds: $727M → $522M (-$205M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$31.4M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
+$10.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$8.7M |
| 4 |
Morgan Stanley
New York
|
+$5.2M |
| 5 |
Walleye Capital
New York
|
+$3.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$30M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$6.71M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
-$6.7M |
| 4 |
ACM
Atika Capital Management
New York
|
-$6.33M |
| 5 |
Two Sigma Investments
New York
|
-$2.9M |
AERI Hedge Fund Activity: Q3 2021 in Review
137 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2021, worth a combined $522M — down 28% from $727M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of AERI and 18 opened new positions — a net loss of 4 holders — while 38 trimmed existing stakes and 52 added.
The largest buyer was Deerfield Management, adding an estimated $31.4M. The largest seller was Loomis, Sayles & Company, exiting entirely with an estimated $30M sold.
- 137 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2021, down from 142 in Q2 2021.
- Funds reported $522M of Aerie Pharmaceuticals stock for Q3 2021, down 28% quarter-over-quarter.
- 18 funds opened new Aerie Pharmaceuticals positions in Q3 2021 and 22 closed out, a net change of -4 holders.
- The largest Aerie Pharmaceuticals buyer in Q3 2021 was Deerfield Management, an estimated $31.4M added.
- The largest Aerie Pharmaceuticals seller in Q3 2021 was Loomis, Sayles & Company, an estimated $30M sold.
Based on aggregated 13F filings for Q3 2021.